豪掷近5亿美元辉瑞(PFE.US)牵手中国biotech，加码在华减肥药市场

Group 1 - Pfizer has entered into an agreement with Hangzhou Xianweida Biotechnology Co., Ltd. to obtain exclusive commercialization rights for the weight loss therapy ecnoglutide in China, aiming to strengthen its position in the high-growth weight loss market [1] - The total deal value can reach up to $495 million, which includes an upfront payment and milestone-based subsequent payments, although specific details were not disclosed [1] - The collaboration is part of Pfizer's long-term strategic layout in the metabolic field to meet the growing demand from Chinese patients, as obesity affects 14.1% of adults in China and is a priority in the government's "Healthy China" initiative [1] Group 2 - Ecnoglutide operates similarly to Novo Nordisk's semaglutide (Ozempic) by mimicking a natural hormone called GLP-1 to regulate blood sugar and suppress appetite, but it is believed to be more effective and safer due to its slightly different structure [2] - In a late-stage study, ecnoglutide achieved weight loss results comparable to Eli Lilly's tirzepatide (Zepbound) [2] Group 3 - According to the agreement with Pfizer, Xianweida will remain responsible for the development, registration, production, and supply of the drug [3]